Tishler M, Nyman J, Wahren M, Yaron M
Department of Rheumatology, Ichilov Hospital, Tel Aviv University Sackler School of Medicine, Israel.
Rheumatol Int. 1997;17(4):133-5. doi: 10.1007/s002960050023.
The purpose of our study was to investigate the significance of the presence of anti-Ro antibodies found by us in an earlier study of rheumatoid arthritis (RA) patients with gold-induced side effects. Sera of 29 anti-Ro (SSA) positive RA patients who had gold-induced side effects were studied. All sera were examined by Western blot using recombinant antigens, encoding the Ro 60 kD and the La proteins. HLA typing was done in all patients. Thirteen patients reacted only with the Ro 52 kD antigen and all had severe skin eruptions caused by gold therapy. Another ten patients who reacted only with the Ro 60 kD antigen had other side effects to gold (six had proteinuria and four leucopenia). Six patients who reacted to all three antigens (Ro 52 kD, Ro 60 kD and La) had secondary Sjögren's syndrome. No significant statistical differences were noted in the incidence of HLA-DR3 between the subgroups of patients. Our data indicated that antibodies to the Ro 52 kD antigen are associated with skin eruptions in RA patients treated with gold.
我们研究的目的是调查在先前一项针对出现金制剂副作用的类风湿关节炎（RA）患者的研究中发现的抗Ro抗体的意义。对29例出现金制剂副作用的抗Ro（SSA）阳性RA患者的血清进行了研究。所有血清均使用编码Ro 60 kD和La蛋白的重组抗原通过蛋白质印迹法进行检测。对所有患者进行了HLA分型。13例患者仅与Ro 52 kD抗原发生反应，且均因金制剂治疗出现严重皮疹。另外10例仅与Ro 60 kD抗原发生反应的患者出现了金制剂的其他副作用（6例出现蛋白尿，4例出现白细胞减少）。6例对所有三种抗原（Ro 52 kD、Ro 60 kD和La）均有反应的患者患有继发性干燥综合征。各亚组患者之间HLA-DR3的发生率未发现显著统计学差异。我们的数据表明，在用金制剂治疗的RA患者中，抗Ro 52 kD抗原的抗体与皮疹有关。
